Effect of Bifidobacterium Triple Live Bacteria Combined with Mesalazine in Patients with Ulcerative Colitis
Objective:To analyze the therapeutic effect of Bifidobacterium Triple Live Bacteria combined with Mesalazine in patients with ulcerative colitis(UC).Method:A total of 94 UC patients admitted to the 971th Hospital of the Chinese People's Liberation Army Navy from March 2020 to March 2021 were selected as the study objects,and they were divided into two groups according to the random number table method,47 cases in each group.The control group was treated with Mesalazine,while the observation group was treated with Bifidobacterium Triple Live Bacteria combined with Mesalazine.The clinical efficacy,T lymphocyte subpopulation levels,plasma fibrinogen(FIB)levels,inflammatory factor levels and adverse reactions between two groups were compared.Result:The clinical efficacy of the observation group(95.74%)was significantly higher than that of the control group(82.98%),the difference was statistically significant(P<0.05).After treatment,the levels of T lymphocyte subsets in the observation group were significantly higher than those in the control group,while the levels of plasma FIB and inflammatory factors were significantly lower than those in the control group,the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions(6.38%vs 10.64%)between the groups(P>0.05).Conclusion:The use of Bifidobacterium Triple Live Bacteria combined with Mesalazine in the treatment of UC can significantly improve the patients'condition,enhance the body's immunity,reduce inflammatory reactions,and do not increase the adverse reaction.
Ulcerative colitisBifidobacterium Triple Live BacteriaMesalazineInflammatory factorsImmunity
万方数据
维普
